An open-source AlphaSense alternative for biopharma
AlphaSense is a horizontal market-intelligence search platform — hundreds of millions of documents across every industry, with generative search that anchors answers to source snippets. It's good at what it does. OpenBio-Intel is the vertical, open-source take on the same core promise for one domain: biopharma clinical and regulatory intelligence.
The same core contract
AlphaSense's defining feature is that every generated claim links to its source snippet. OpenBio-Intel makes the same commitment structurally: the extraction schema forbids answers from model memory, every Smart Table row carries clickable citations (NCT id, PMCID, filing URL), and per-corpus grounding gates reject answers whose retrieved evidence shares no vocabulary with the question.
What being vertical + open buys you
| OpenBio-Intel | AlphaSense | |
|---|---|---|
| Scope | Deep on biopharma: trials, FDA (approvals and CRLs), literature, filings, FAERS, exclusivity | Broad, cross-industry documents |
| Structure | Structured comparison grids, landscape matrices, catalyst timelines — not just search + snippets | Document search + generative summaries |
| Hosting | Yours. Queries stay on your infrastructure | Vendor SaaS |
| Methodology | Open code, committed benchmarks | Proprietary |
| Extensibility | Fork it; add a source; swap the models | Closed |
| Agents | MCP server — usable inside Claude | Human UI first |
| Price | Self-hosted + LLM API costs | Enterprise subscription |
What AlphaSense does that this doesn't
Broker research and expert-call transcript libraries (licensed content an open project cannot redistribute), cross-industry coverage, mobile apps, enterprise onboarding. If your workflow lives on licensed sell-side content, an open-source tool is not a substitute.
Try the difference in five minutes
The quickstart gets you a running instance with a demo corpus. Ask it a question, click a citation, then open research_agent.py and read exactly why you got that answer. That last step is the one no closed platform can offer.